Mary Lynne Hedley
Known title: DirectorCIK: 0001340823
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Eli Lilly gets EMA backing for Foundayo obesity pill. The European Medicines Agency panel issued a positive opinion on Lilly's Foundayo pill for obesity and type 2 diabetes, clearing a regulatory hurdle for the drug. Recent coverage also notes Lilly's broader pipeline beyond Zepbound and rising competitive pressure on Novo Nordisk. In parallel, the company's largest shareholder announced a $347 million stock sale, adding another layer of market interest.
Transaction History
| VEEV | ▲ Buy | Option Exercise | 477 | $0 | 9/1/2026 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 262 | $0 | 6/1/2026 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 262 | $0 | 3/1/2026 | View on chart |
| LLY | ▲ Buy | Grant | 9 | $10K | 12/15/2025 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 263 | $0 | 12/1/2025 | View on chart |
| LLY | ▲ Buy | Grant | 10 | $10K | 11/17/2025 | View on chart |
| LLY | ▲ Buy | Grant | 215 | $220K | 11/17/2025 | View on chart |
| LLY | ▲ Buy | Grant | 12 | $10K | 10/20/2025 | View on chart |
| LLY | ▲ Buy | Grant | 13 | $10K | 9/15/2025 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 262 | $0 | 9/1/2025 | View on chart |
| LLY | ▲ Buy | Grant | 14 | $10K | 8/18/2025 | View on chart |
| LLY | ▲ Buy | Grant | 13 | $10K | 7/21/2025 | View on chart |
| LLY | ▲ Buy | Grant | 12 | $10K | 6/16/2025 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 343 | $0 | 6/1/2025 | View on chart |
| LLY | ▲ Buy | Grant | 13 | $10K | 5/19/2025 | View on chart |
| LLY | ▲ Buy | Grant | 12 | $10K | 4/21/2025 | View on chart |
| LLY | ▲ Buy | Grant | 12 | $10K | 3/17/2025 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 342 | $0 | 3/1/2025 | View on chart |
| LLY | ▲ Buy | Grant | 12 | $10K | 2/18/2025 | View on chart |
| LLY | ▲ Buy | Grant | 13 | $10K | 1/21/2025 | View on chart |
| LLY | ▲ Buy | Grant | 13 | $10K | 12/16/2024 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 343 | $0 | 12/1/2024 | View on chart |
| LLY | ▲ Buy | Grant | 14 | $10K | 11/18/2024 | View on chart |
| LLY | ▲ Buy | Grant | 303 | $220K | 11/18/2024 | View on chart |
| LLY | ▲ Buy | Grant | 11 | $10K | 10/21/2024 | View on chart |
| LLY | ▲ Buy | Grant | 11 | $10K | 9/16/2024 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 343 | $0 | 9/1/2024 | View on chart |
| LLY | ▲ Buy | Grant | 11 | $10K | 8/19/2024 | View on chart |
| LLY | ▲ Buy | Grant | 10 | $10K | 7/15/2024 | View on chart |
| LLY | ▲ Buy | Grant | 11 | $10K | 6/17/2024 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 302 | $0 | 6/1/2024 | View on chart |
| LLY | ▲ Buy | Grant | 13 | $10K | 5/20/2024 | View on chart |
| LLY | ▲ Buy | Grant | 13 | $10K | 4/15/2024 | View on chart |
| LLY | ▲ Buy | Grant | 13 | $10K | 3/18/2024 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 302 | $0 | 3/1/2024 | View on chart |
| LLY | ▲ Buy | Grant | 13 | $10K | 2/20/2024 | View on chart |
| LLY | ▲ Buy | Grant | 16 | $10K | 1/16/2024 | View on chart |
| VEEV | ▼ Sell | Open Market | 42 | $8K | 12/28/2023 | View on chart |
| VEEV | ▼ Sell | Open Market | 41 | $8K | 12/27/2023 | View on chart |
| LLY | ▲ Buy | Grant | 17 | $10K | 12/18/2023 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 303 | $0 | 12/1/2023 | View on chart |
| LLY | ▲ Buy | Grant | 17 | $10K | 11/20/2023 | View on chart |
| LLY | ▲ Buy | Grant | 335 | $200K | 11/20/2023 | View on chart |
| LLY | ▲ Buy | Grant | 16 | $10K | 10/16/2023 | View on chart |
| LLY | ▲ Buy | Grant | 17 | $10K | 9/18/2023 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 302 | $0 | 9/1/2023 | View on chart |
| LLY | ▲ Buy | Grant | 18 | $10K | 8/21/2023 | View on chart |
| LLY | ▲ Buy | Grant | 22 | $10K | 7/17/2023 | View on chart |
| VEEV | ▼ Sell | Open Market | 138 | $29K | 7/13/2023 | View on chart |
| VEEV | ▼ Sell | Open Market | 92 | $19K | 7/12/2023 | View on chart |
| LLY | ▲ Buy | Grant | 22 | $10K | 6/20/2023 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 326 | $0 | 6/1/2023 | View on chart |
| LLY | ▲ Buy | Grant | 23 | $10K | 5/15/2023 | View on chart |
| LLY | ▲ Buy | Grant | 27 | $10K | 4/17/2023 | View on chart |
| LLY | ▲ Buy | Grant | 30 | $10K | 3/20/2023 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 327 | $0 | 3/1/2023 | View on chart |
| LLY | ▲ Buy | Grant | 30 | $10K | 2/21/2023 | View on chart |
| LLY | ▲ Buy | Grant | 28 | $10K | 1/17/2023 | View on chart |
| LLY | ▲ Buy | Grant | 28 | $10K | 12/19/2022 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 326 | $0 | 12/1/2022 | View on chart |
| LLY | ▲ Buy | Grant | 27 | $10K | 11/21/2022 | View on chart |
| LLY | ▲ Buy | Grant | 332 | $120K | 11/21/2022 | View on chart |
| LLY | ▲ Buy | Grant | 30 | $10K | 10/17/2022 | View on chart |
| LLY | ▲ Buy | Grant | 33 | $10K | 9/19/2022 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 327 | $0 | 9/1/2022 | View on chart |
| LLY | ▲ Buy | Grant | 32 | $10K | 8/15/2022 | View on chart |
| LLY | ▲ Buy | Grant | 31 | $10K | 7/18/2022 | View on chart |
| LLY | ▲ Buy | Grant | 33 | $10K | 6/21/2022 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 197 | $0 | 6/1/2022 | View on chart |
| LLY | ▲ Buy | Grant | 18 | $5K | 5/16/2022 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 197 | $0 | 3/1/2022 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 197 | $0 | 12/1/2021 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 197 | $0 | 9/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Veeva Gains Investor Attention Amid R&D Growth and AI Focus
Veeva Systems is drawing investor interest as analysts note strong R&D growth and a positive outlook. The company has secured a major research partner that now uses its software as the default clinical platform, and a recent IQVIA deal expands its market reach. Large institutional investors are also increasing exposure to Veeva as part of an AI software play.
Veeva Gains Investor Attention Amid R&D Growth and AI Focus. Veeva Systems is drawing investor interest as analysts note strong R&D growth and a positive outlook. The company has secured a major research partner that now uses its software as the default clinical platform, and a recent IQVIA deal expands its market reach. Large institutional investors are also increasing exposure to Veeva as part of an AI software play.